anchor Baxter NN, Kennedy EB, Bergsland E, et al. "Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update." J Clin Oncol. 2022;40(8):892-910. doi:10.1200/JCO.21.02538. The current ASCO clinical practice guideline governing the exact decision this sub-topic interrogates: whether/how to give adjuvant chemotherapy after resection of stage II colon cancer. Its directly load-bearing statement for the sub-topic is that circulating tumor DNA was identified by the Expert Panel as an emerging potential PREDICTIVE factor, but that insufficient evidence of its chemotherapy-predictive value was available to warrant including ctDNA in the guideline's list of high-risk features used to recommend adjuvant chemotherapy; the panel explicitly anticipated that prospective-trial data on ctDNA would be forthcoming and incorporated in a future guideline version. The surrounding recommendation framework is that routine adjuvant chemotherapy is NOT recommended for non-high-risk stage II colon cancer, with adjuvant therapy offered/discussed via shared decision-making for high-risk features (e.g., T4 disease), and that the absolute benefit of adjuvant chemotherapy in stage II is small. Bearing on the sub-topic: this node is distinct from every trial/registry/protocol node already in the graph (DYNAMIC, GALAXY/CIRCULATE-Japan, BESPOKE, COBRA, ALTAIR, DYNAMIC-III, CIRCULATE-US, PEGASUS, MEDOCC-CrEATE, Tie 2016) because it is the authoritative GUIDELINE baseline against which the trial spine's de-escalation/escalation evidence is to be judged. It supplies (a) the standard-of-care comparator that DYNAMIC's "standard clinicopathologic management" arm operationalizes, (b) documentary evidence that, as of the guideline, ctDNA was NOT yet endorsed for routine stage II adjuvant decision-making, establishing the contested-decision gap the sub-topic's evidence chain aims to close, and (c) the predictive-vs-prognostic framing that the observational (GALAXY/Kotani/BESPOKE) and randomized (DYNAMIC) nodes are marshalled to satisfy. Caveats: it is a guideline/consensus document, not primary evidence — its weight is normative/synthetic rather than a trial result; and it is a 2022 snapshot that predates the mature DYNAMIC 5-year readout and most of the spine's later readouts, so a future ASCO guideline update incorporating ctDNA is the natural propose_supersedes target.

nod_39527581-3bc2-4702-b068-4cece6c67f3d

Source

No active edges touch this node yet — an isolated point in the graph (or, for a freshly accepted anchor, awaiting an excerpt).